Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity

Volumn 3, Issue , 2010, Pages 49-53

  Kushner, Pamela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes management; Dipeptidyl peptidase 4 inhibitors; Hypoglycemia; Incretin; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMYLIN AGONIST; ANTIDIABETIC AGENT; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLINIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 AGONIST; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN HYPOGLYCEMIA; MORBIDITY; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREVALENCE; RISK REDUCTION; SIDE EFFECT;

EID: 77953471610     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmso.s10013     Document Type: Article

References (20)

1. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
2. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630-2633.
3. Skyler JS, Bergenstal R, Bonow RO, et al. American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32:187-192.
4. Davis SN, Mann S, Briscoe VJ, Ertl AC, Tate DB. Effects of intensive therapy and antecedent hypoglycemia on counterregulatory responses to hypoglycemia in type 2 diabetes. Diabetes. 2009;58:701-709.
5. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94:709-728.
6. McCrimmon RJ, Deary IJ, Gold AE, et al. Symptoms reported during experimental hypoglycaemia: Effect of method of induction of hypoglycaemia and of diabetes per se. Diabet Med. 2003;20:507-509.
7. Briscoe VJ, Davis SN. Hypoglycemia in type 1 and type 2 diabetes: Physiology, pathophysiology and management. Clin Diabetes. 2006;24:115-121.
8. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ. 2010 Jan 8;340:b4909. doi: 10.1136.
9. Miller ME, Bonds DE, Gerstein HC, et al. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: Post hoc epidemiological analysis of the ACCORD study. BMJ. 2010;8;340: b5444. doi: 10.1136.
10. Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
11. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring. Diabetes Care. 2003;26:1485-1489.
12. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
13. Mellbin LG, Malmberg K, Waldenstrom A, Wedel H, Ryden L, DIGAMI 2 Investigators. Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: A report from the DIGAMI 2 trial. Heart. 2009;95:721-727.
14. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565-1572.
15. American Diabetes Association. Standards of medical care in diabetes 2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
16. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An algorithm for glycemic control. Endocr Pract. 2009;15:540-559.
17. National Institute for Health and Clinical Excellence. 2009. Type 2 diabetes: Newer agents for blood glucose control in type 2 diabetes. Available at: http://www.nice.org.uk/nicemedia/pdf/CG87ShortGuideline.pdf. Accessed September 30, 2009.
18. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
19. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009.
20. Drucker DJ, Buse JB, Taylor K, et al; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet. 2008;372:1240-1250.